One of the representative drugs used for the maintenance treatment of advanced newly diagnosed ovarian cancer is bevacizumab, a humanized vascular endothelial growth factor (VEGF)-neutralizing monoclonal antibody. The gene discussed is VEGFA; the disease is ovarian carcinoma.